arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

AMARIN CORP PLCUK

AMRN
$11.54 ▼ -0.77 (-6.26%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

AMARIN CORP PLCUK faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.8B
Dividend Yield —
Revenue Growth -6.5% ↗
Op. Margin -23.5% ↗
ROIC -11.8% ↗
FCF / Share $0.02 ↗
Trailing P/E —
Price / Book 10.5x
FCF Yield 0.1%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$213.65M
↓ -6.5% —
Net Income Profit after all expenses
$-38.80M
↑ +52.8% —
Operating Margin Operating profit as % of sales
-23.5%
↑ +41.5% 9th
FCF / Share Free cash flow per share
$0.02
↑ +121.5% —
Long-Term Debt Long-term obligations
$49.70M
↓ -37.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
19
Returns
35
Financial Health
1
Cash Quality ↑
17

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 69 quarters